<DOC>
	<DOCNO>NCT03103815</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy Amivita , coumpound amino acid vitamines patient Amyotrophic lateral sclerosis ( ALS ) ALS . The secondary objective measure quality life intervention . This self-controlled clinical trial . Twenty patient ALS center already receive riluzole treatment condition worsen receive treatment 1o month . The evaluate investigator blind treatment assignment . Primary outcome measure adverse event , ALS Functional Rating Scale-Revised ( ALSFRS-R ) , survival . Subjects also assess enrollment study end weight loss , force vital capacity ( FVC ) , quality life grip strength .</brief_summary>
	<brief_title>Trial Amivita Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) progressive neurodegenerative disorder affect upper low motor neuron . Survival typically 2 5 year symptom onset ; death usually respiratory paralysis . Standard therapy Riluzole 100 mg/day , FDA approve treatment ALS small effect survival . There strong need effective therapy ALS . In previous study , show Amivita , coumpound amino acid vitamines , effective neuronal injury ( unpublished data ) . We since use regimen treat ALS patient . Our retrospective analysis ( unpublished data ) treat patient indicates regimen slow progression ALS . We propose self-controlled clinical trial study safety efficacy Amivita . Secondary outcome measure include weight quality life . Twenty subject ALS center already receive riluzole receive treatment 12 month . The evaluate investigator blind treatment assignment . Primary outcome measure adverse event , ALS Functional Rating Scale-Revised ( ALSFRS-R ) , survival . Secondary outcome measure include body weight , force vital capacity ( FVC ) , quality life grip strength . The total study length first enrol subject approximately 6 month . Participants study subject familial sporadic ALS diagnose probable , definite , accord World Federation Neurology El Escorial criterion . Diagnostic Inclusionary/Exclusionary criterion clearly outline protocol .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Patients must men woman age 18 70 year 2 . Patient clinical definite / probable ALS hospital list protocol 3 . Women child bear potential must negative pregnancy test ( urine test acceptable ) 4 . Willing comply study visit 5 . Will take riluzole study period 6 . Be able sign inform consent document 1 . Myotonic dystrophy 2 . Myasthenia gravis 3 . Postpoliomyelitis syndrome 4 . Multifocal motor neuropathy without conduction block 5 . Hirayama disease 6 . Kennedy disease 7 . Hereditary spastic paraplegia 8 . Syringomyelia 9 . Spinal cord brain stem tumor 10 . Paraneoplastic syndrome 11 . Severe liver disease 12 . Infection , severe diarrhea vomit 13 . Serious heart lung disease malignant tumor history 14 . HIV infection 15 . Pregnancy breastfeed 16 . Have ability communicate 17 . Have participate clinical trial within 4 week 18 . Any form substance abuse , psychiatric disorder , condition , opinion investigator , may interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Amyotrophic lateral sclerosis , survival , adverse event</keyword>
</DOC>